Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk

References

• MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med.2006311e44217132052
   PubMed Web of Science ®Google Scholar
• Lloyd-JonesDAdamsRJBrownTMAmerican Heart Association Statistics Committee and Stroke Statistics SubcommitteeHeart disease and stroke statistics – 2010 update: a report from the American Heart AssociationCirculation20101217e46e21520019324
   PubMed Web of Science ®Google Scholar
• LealJLuengo-FernándezRGrayAPetersenSRaynerMEconomic burden of cardiovascular diseases in the enlarged European UnionEur Heart J200627131610161916495286
   PubMed Web of Science ®Google Scholar
• Luengo-FernándezRLealJGrayAPetersenSRaynerMCost of cardiovascular diseases in the United KingdomHeart200692101384138916702172
   PubMed Web of Science ®Google Scholar
• StaessenJALiYThijsLWangJGBlood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trialsHypertens Res200528538540716156503
   PubMed Web of Science ®Google Scholar
• UngerTThe role of the renin-angiotensin system in the development of cardiovascular diseaseAm J Cardiol.2002892A3A9A
   PubMed Web of Science ®Google Scholar
• DzauVJAntmanEMBlackHRThe cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease)Circulation2006114252850287017179034
   PubMed Web of Science ®Google Scholar
• SchmiederREHilgersKFSchlaichMPSchmidtBMRenin-angiotensin system and cardiovascular riskLancet200736995681208121917416265
   PubMed Web of Science ®Google Scholar
• MontecuccoFPendeAMachFThe renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studiesMediators Inflamm.2009 Article ID: 752406.
   Google Scholar
• ChobanianAVBakrisGLBlackHRJoint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureNational Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension20034261206125214656957
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence2006Hypertension: management of hypertension in primary care NICE clinical guideline 34 (Partial update of NICE clinical guideline 18). Available from: http://www.nice.org.uk/CG034. Accessed April 20, 2010.
   Google Scholar
• ManciaGDe BackerGDominiczakAThe task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial HypertensionEur Heart J200728121462153617562668
   PubMed Web of Science ®Google Scholar
• ManciaGLaurentSAgabiti-RoseiEEuropean Society of HypertensionReappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force documentJ Hypertens200927112121215819838131
   PubMed Web of Science ®Google Scholar
• SolomonSDAppelbaumEManningWJAliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophyCirculation2009119453053719153265
   PubMed Web of Science ®Google Scholar
• WeintraubHSTranHSchwartzbardAPotential benefits of aliskiren beyond blood pressure reductionCardiol Rev2011192909421285669
   PubMed Web of Science ®Google Scholar
• DzauVJAntmanEMBlackHRThe cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directionsCirculation2006114252871289117179035
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJBoschJDaviesRDagenaisGEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med2000342314515310639539
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation Study InvestigatorsEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudyLancet2000355920025325910675071
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRCollaborative Study GroupRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013451285186011565517
   PubMed Web of Science ®Google Scholar
• ParvingHHLehnertHBröchner-MortensenJGomisRAndersenSArnerPIrbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study GroupThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med20013451287087811565519
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDRENAAL Study InvestigatorsEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• DahlöfBDevereuxRBKjeldsenSELIFE Study GroupCardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• FoxKMEURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease InvestigatorsEfficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)Lancet2003362938678278813678872
   PubMed Web of Science ®Google Scholar
• BarnettAHBainSCBouterPDiabetics Exposed to Telmisartan and Enalapril Study GroupAngiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathyN Engl J Med2004351191952196115516696
   PubMed Web of Science ®Google Scholar
• PoulterNRWedelHDahlöfBASCOT InvestigatorsRole of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)Lancet2005366948990791316154017
   PubMed Web of Science ®Google Scholar
• DahlöfBSeverPSPoulterNRASCOT InvestigatorsPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet2005366948989590616154016
   PubMed Web of Science ®Google Scholar
• BakrisGBurgessEWeirMDavidaiGKovalSAMADEO Study InvestigatorsTelmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathyKidney Int200874336436918496508
   PubMed Web of Science ®Google Scholar
• ONTARGET InvestigatorsYusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• YusufSTeoKAndersonCTelmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) InvestigatorsEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet200837296441174118318757085
   PubMed Web of Science ®Google Scholar
• HanonSVijayaramanPSonnenblickEHLe JemtelTHPersistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failureJ Renin Angiotensin Aldosterone Syst20001214715011967806
   PubMedGoogle Scholar
• ChenRIwaiMWuLImportant role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injuryHypertension200342454254712963679
   PubMed Web of Science ®Google Scholar
• NussbergerJCugnoMCicardiMBradykinin-mediated angioedemaN Engl J Med2002347862162212192030
   PubMed Web of Science ®Google Scholar
• SteckelingsUMKaschinaEUngerTThe AT2 receptor – a matter of love and hatePeptides20052681401140916042980
   PubMed Web of Science ®Google Scholar
• LawMRMorrisJKWaldNJUse of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBMJ2009338b166519454737
   PubMed Web of Science ®Google Scholar
• OngHTAre angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?J Am Board Fam Med200922668669719897698
   PubMed Web of Science ®Google Scholar
• DicpinigaitisPVAngiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelinesChest20061291 Suppl169S173S16428706
   PubMed Web of Science ®Google Scholar
• MillerDROliveriaSABerlowitzDRFinckeBGStangPLillienfeldDEAngioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitorsHypertension20085161624163018413488
   PubMed Web of Science ®Google Scholar
• WeberMAMesserliFHAngiotensin-converting enzyme inhibitors and angioedema: estimating the riskHypertension20085161465146718413486
   PubMed Web of Science ®Google Scholar
• MorimotoTGandhiTKFiskioJMAn evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitorsJ Eval Clin Pract200410449950915482412
   PubMed Web of Science ®Google Scholar
• MatcharDBMcCroryDCOrlandoLASystematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertensionAnn Intern Med20081481162917984484
   PubMed Web of Science ®Google Scholar
• ChaputAJPersistency with angiotensin receptor blockers (ARB) versus other antihypertensives (AHT) using the Saskatchewan databaseCan J Cardiol200016Suppl F194A
   Google Scholar
• RiesUJMihmGNarrB6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationshipsJ Med Chem19933625404040518258826
   PubMed Web of Science ®Google Scholar
• KurtzTWPravenecMMolecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin systemAm J Hypertens200821885285918535538
   PubMed Web of Science ®Google Scholar
• de la SierraARamCVIntroduction: The pharmacological profile of eprosartan – implications for cerebrovascular and cardiovascular risk reductionCurr Med Res Opin200723Suppl 5S1S318093407
   PubMedGoogle Scholar
• SongJCWhiteCMOlmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertensionFormulary200135487499
   Google Scholar
• BurnierMTelmisartan: a different angiotensin II receptor blocker protecting a different population?J Int Med Res20093761662167920146864
   PubMed Web of Science ®Google Scholar
• Edarbi Prescribing Information (FDA) Revised April 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/200796s001lbl.pdf. Accessed August 4, 2011.
   Google Scholar
• AsmarRTargeting effective blood pressure control with angiotensin receptor blockersInt J Clin Pract200660331532016494647
   PubMed Web of Science ®Google Scholar
• KakutaHSudohKSasamataMYamagishiSTelmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockersInt J Clin Pharmacol Res2005251414615864875
   PubMedGoogle Scholar
• OjimaMIgataHTanakaMIn vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studiesJ Pharmacol Exp Ther2011336380180821123673
   PubMed Web of Science ®Google Scholar
• WienenWEntzerothMvan MeelJCAA review on telmisartan: a novel, long-acting angiotensin II-receptor antagonistCardiovasc Drug Rev200018127154
   Google Scholar
• BurnierMBrunnerHRAngiotensin II receptor antagonistsLancet2000355920463764510696996
   PubMed Web of Science ®Google Scholar
• BrunnerHRThe new oral angiotensin II antagonist olmesartan medoxomil: a concise overviewJ Hum Hypertens200216Suppl 2S13S1611967728
   PubMedGoogle Scholar
• IsrailiZHClinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertensionJ Hum Hypertens200014Suppl 1S73S8610854085
   PubMed Web of Science ®Google Scholar
• StangierJSuCAFraunhoferATetzloffWPharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteersJ Clin Pharmacol20004012 Pt 11338134611185632
   PubMed Web of Science ®Google Scholar
• UngerTKaschinaEDrug interactions with angiotensin receptor blockers: a comparison with other antihypertensivesDrug Saf2003261070772012862505
   PubMed Web of Science ®Google Scholar
• BensonSCPershadsinghHAHoCIIdentification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activityHypertension2004435993100215007034
   PubMed Web of Science ®Google Scholar
• FrenchCJZamanAKSobelBEThe angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaquesJ Cardiovasc Pharmacol201158214314821558880
   PubMed Web of Science ®Google Scholar
• ChenSGeYSiJRifaiADworkinLDGongRCandesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockadeKidney Int20087491128113818650791
   PubMed Web of Science ®Google Scholar
• HamadaTIchidaKHosoyamadaMUricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patientsAm J Hypertens200821101157116218670416
   PubMed Web of Science ®Google Scholar
• AldermanMAiyerKJUric acid: role in cardiovascular disease and effects of losartanCurr Med Res Opin200420336937915025846
   PubMed Web of Science ®Google Scholar
• HøieggenAAldermanMHKjeldsenSELIFE Study GroupThe impact of serum uric acid on cardiovascular outcomes in the LIFE studyKidney Int20046531041104914871425
   PubMed Web of Science ®Google Scholar
• FabiaMJAbdillaNOltraRFernandezCRedonJAntihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoringJ Hypertens20072571327133617563549
   PubMed Web of Science ®Google Scholar
• OparilSWilliamsDChrysantSGMarburyTCNeutelJComparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertensionJ Clin Hypertens (Greenwich)20013528329111588406
   PubMedGoogle Scholar
• SmithDHDubielRJonesMUse of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartanAm J Cardiovasc Drugs200551415015631537
   PubMedGoogle Scholar
• WeirMRPunziHAFlackJMA randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertensionPostgrad Med20111231808721293087
   PubMed Web of Science ®Google Scholar
• GilesTDOparilSSilfaniTNWangAWalkerJFComparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertensionJ Clin Hypertens (Greenwich)20079318719517341994
   PubMedGoogle Scholar
• DestroMScabrosettiRVanasiaAMugelliniAComparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoringAdv Ther2005221324315943220
   PubMed Web of Science ®Google Scholar
• SasakiTNodaYYasuokaYComparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndromeHypertens Res200831592192918712048
   PubMed Web of Science ®Google Scholar
• de LuisDACondeRGonzález-SagradoMEffects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patientsNutr Hosp201025227527920449538
   PubMed Web of Science ®Google Scholar
• BakrisGLSicaDWeberMThe comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressureJ Clin Hypertens (Greenwich)2011132818821272195
   PubMed Web of Science ®Google Scholar
• WhiteWBWeberMASicaDEffects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertensionHypertension201157341342021282560
   PubMed Web of Science ®Google Scholar
• CorraoGZambonAParodiADiscontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in ItalyJ Hypertens200826481982418327094
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMVALUE Trial GroupOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436394262022203115207952
   PubMed Web of Science ®Google Scholar
• SawadaTYamadaHDahlöfBMatsubaraHKyoto Heart Study GroupEffects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: Kyoto Heart StudyEur Heart J200930202461246919723695
   PubMed Web of Science ®Google Scholar
• RossingKChristensenPKAndersenSHovindPHansenHPParvingHHIrbesartan in Patients with Type 2 Diabetes and Microalbuminuria StudyComparative effects of irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria studyDiabetes Care200326356957412610003
   PubMed Web of Science ®Google Scholar
• GalleJSchwedhelmEPinnettiSBögerRHWannerCVIVALDI investigatorsAntiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathyNephrol Dial Transplant200823103174318318450829
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan in Acute Myocardial Infarction Trial InvestigatorsValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGValsartan Heart Failure Trial InvestigatorsA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med2001345231667167511759645
   PubMed Web of Science ®Google Scholar
• DicksteinKKjekshusJOPTIMAAL Steering Committee of the OPTIMAAL Study GroupEffects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist LosartanLancet2002360933575276012241832
   PubMed Web of Science ®Google Scholar
• PittBPoole-WilsonPASegalREffect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE IILancet200035592151582158710821361
   PubMed Web of Science ®Google Scholar
• KonstamMANeatonJDDicksteinKHEAAL InvestigatorsEffects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trialLancet200937497041840184819922995
   PubMed Web of Science ®Google Scholar
• PfefferMASwedbergKGrangerCBCHARM Investigators and CommitteesEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet2003362938675976613678868
   PubMed Web of Science ®Google Scholar
• YusufSPfefferMASwedbergKCHARM Investigators and CommitteesEffects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialLancet2003362938677778113678871
   PubMed Web of Science ®Google Scholar
• MassieBMCarsonPEMcMurrayJJI-PRESERVE InvestigatorsIrbesartan in patients with heart failure and preserved ejection fractionN Engl J Med2008359232456246719001508
   PubMed Web of Science ®Google Scholar
• OwanTEHodgeDOHergesRMJacobsenSJRogerVLRedfieldMMTrends in prevalence and outcome of heart failure with preserved ejection fractionN Engl J Med2006355325125916855265
   PubMed Web of Science ®Google Scholar
• CarlbergBSamuelssonOLindholmLHAtenolol in hypertension: is it a wise choice?Lancet200436494461684168915530629
   PubMed Web of Science ®Google Scholar
• MochizukiSDahlöfBShimizuMJikei Heart Study GroupValsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality studyLancet200736995711431143917467513
   PubMed Web of Science ®Google Scholar
• PapademetriuVFarsangCElmfeldDStudy on Cognition and Prognosis in the Elderly study groupStroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE)J Am Coll Cardiol20044461175118015364316
   PubMed Web of Science ®Google Scholar
• KizerJRDahlöfBKjeldsenSEStroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension studyHypertension2005451465215583076
   PubMed Web of Science ®Google Scholar
• SchraderJLüdersSKulschewskiAAcute Candesartan Cilexetil Therapy in Stroke Survivors Study GroupThe ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke SurvivorsStroke20033471699170312817109
   PubMed Web of Science ®Google Scholar
• YusufSDienerHCSaccoRLPRoFESS Study GroupTelmisartan to prevent recurrent stroke and cardiovascular eventsN Engl J Med2008359121225123718753639
   PubMed Web of Science ®Google Scholar
• HallerHItoSIzzoJLROADMAP Trial InvestigatorsOlmesartan for the delay or prevention of microalbuminuria in Type 2 diabetesN Engl J Med20113641090791721388309
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationFDA drug safety communication: ongoing safety review of Benicar and cardiovascular events6112010 Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm215222.htm. Accessed July 28, 2011.
   Google Scholar
• KrumHCarsonPFarsangCEffect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from VAL-HeFTEur J Heart Fail20046793794515556056
   PubMed Web of Science ®Google Scholar
• CiceGDi BenedettoAD’IsaSEffects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failureJ Am Coll Cardiol201056211701170821070920
   PubMed Web of Science ®Google Scholar
• LawMRWaldNJMorrisJKJordanREValue of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsBMJ20033267404142712829555
   PubMed Web of Science ®Google Scholar
• FarsangCNaditch-BruleLAvogaroAWhere are we with the management of hypertension? From science to clinical practiceJ Clin Hypertens (Greenwich)2009112667319222670
   PubMed Web of Science ®Google Scholar
• BisognanoJDMcLaughlinTRobertsCSTangSSCalcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: effectiveness in combination with diuretics or beta-blockers for treating hypertensionVasc Health Risk Manag20073557958518078009
   PubMedGoogle Scholar
• MengdenTUenSBramlagePManagement of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utilityVasc Health Risk Manag200951043105820057897
   PubMedGoogle Scholar
• WaldDSLawMMorrisJKBestwickJPWaldNJCombination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trialsAm J Med2009122329030019272490
   PubMed Web of Science ®Google Scholar
• AllemannYFraileBLambertMBarbierMFerberPIzzoJLJrEfficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) studyJ Clin Hypertens (Greenwich)200810318519418326958
   PubMed Web of Science ®Google Scholar
• ChrysantSGMelinoMKarkiSLeeJHeyrmanRThe combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety studyClin Ther200830458760418498909
   PubMed Web of Science ®Google Scholar
• LittlejohnTW3rdMajulCROlveraRStudy InvestigatorsResults of treatment with telmisartan-amlodipine in hypertensive patientsJ Clin Hypertens (Greenwich)200911420721319614805
   PubMed Web of Science ®Google Scholar
• LittlejohnTW3rdMajulCROlveraRStudy InvestigatorsTelmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 × 4 factorial studyPostgrad Med2009121251419332958
   PubMed Web of Science ®Google Scholar
• JamersonKWeberMABakrisGLACCOMPLISH Trial InvestigatorsBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med2008359232417242819052124
   PubMed Web of Science ®Google Scholar
• BakrisGLSarafidisPAWeirMRACCOMPLISH Trial investigatorsRenal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trialLancet201037597211173118120170948
   PubMed Web of Science ®Google Scholar
• VermaSStraussMAngiotensin receptor blockers and myocardial infarctionBMJ200432974771248124915564232
   PubMed Web of Science ®Google Scholar
• de Kare-SilverNAngiotensin medications and MI Rapid response published in BMJ, December 3, 2004. Available from: http://bmj.bmjjournals.com/cgi/eletters/329/7477/1248. Accessed October 7, 2010.
   Google Scholar
• McMurrayJJSwedbergKPfefferMAngiotensin receptor blockers and myocardial infarction Rapid response published in BMJ, December 7, 2004. Available from: http://bmj.bmjjournals.com/cgi/eletters/329/7477/1248. Accessed October 7, 2010.
   Google Scholar
• OpieLHARBs: re-examine the data Rapid response published in BMJ, December 9, 2004. Available from: http://bmj.bmjjournals.com/cgi/eletters/329/7477/1248. Accessed July 19, 2005.
   Google Scholar
• TaalMWFluckRJMcIntyreCWNo consistent evidence that ARBs increase myocardial infarction Available from: http://bmj.bmjjournals.com/cgi/eletters/329/7477/1248. Accessed October 7, 2010.
   Google Scholar
• LeeVCRhewDCDylanMBadamgaravEBraunsteinGDWeingartenSRMeta-analysis: angiotensin AT1 receptor blockers in chronic heart failure and high risk acute myocardial infarctionAnn Intern Med2004141969370415520426
   PubMed Web of Science ®Google Scholar
• VerdecchiaPAngeliFGattobigioRReboldiGDo angiotensin II receptor blockers increase the risk of myocardial infarctionEur Heart J200526222381238616081468
   PubMed Web of Science ®Google Scholar
• VolpeMManciaGTrimarcoBAngiotensin II receptor blockers and myocardial infarction: deeds and misdeedsJ Hypertens200523122113211816269950
   PubMed Web of Science ®Google Scholar
• StraussMHHallASAngiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradoxCirculation2006114883885416923768
   PubMed Web of Science ®Google Scholar
• TsuyukiRTMcDonaldMAAngiotensin receptor blockers do not increase risk of myocardial infarctionCirculation2006114885586016923769
   PubMed Web of Science ®Google Scholar
• GonzalezMAldermanMCohenHSealeyJLaraghJLong-term associations of plasma renin activity with all-cause and cardiovascular mortalityJ Hypertens201129e-Suppl Ae17 (Abstr LB1.1).
   PubMedGoogle Scholar
• MassonSSolomonSAngeliciLVal-Heft InvestigatorsElevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT)J Card Fail2010161296497021111986
   PubMed Web of Science ®Google Scholar
• ChanCPoulterNScanlonMASCOT InvestigatorsThe Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Biomarker ProgrammeJ Hypertens201129e-Suppl Ae17 (Abstr LB1.3).
   PubMedGoogle Scholar
• PhillipsCOKashaniAKoDKFrancisGKrumholzHMAdverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trialsArch Intern Med2007167181930193617923591
   PubMedGoogle Scholar
• KurnikDVesterman-LandesJBialikMHyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community settingClin Ther201133445646421635991
   PubMed Web of Science ®Google Scholar
• SipahiIDebanneSMRowlandDYSimonDIFangJCAngiotensin-receptor blockade and risk of cancer: meta-analysis of randomized controlled trialsLancet Oncol201011762763620542468
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSWeberMAngiotensin-receptor blockade and the risk of cancer. Omission of VALUE trial data invalidates conclusionsLancet Oncol201011982082120816379
   PubMedGoogle Scholar
• BangaloreSKumarSKjeldsenSEAntihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trialsLancet Oncol2010121658221123111
   PubMed Web of Science ®Google Scholar
• ARB Trialists CollaborationEffects of telmisartan, irbesartan, valsartan, candesartan and losartan on cancers in 15 trials enrolling 138,769 individualsJ Hypertens201129462363521358417
   PubMed Web of Science ®Google Scholar
• SiragyHMA current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitorsVasc Health Risk Manag2011729731321633727
   PubMedGoogle Scholar
• VolpeMMorgantiAExecutive Committee of the Italian Society of Hypertension2010 position paper of the Italian Society of Hypertension (SIIA): angiotensin receptor blockers and risk of cancerHigh Blood Press Cardiovasc Prev2011181374021612311
   PubMedGoogle Scholar
• FDA Drug Safety CommunicationNo increase in risk of cancer with certain blood pressure drugs: Angiotensin Receptor Blockers (ARBs)622011 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm257516.htm. Accessed June 9, 2011.
   Google Scholar
• FarsangCFischerJOptimizing antihypertensive therapy by angiotensin receptor blockersFischerJGanellinCRAnalogue-Based Drug DiscoveryWeinheim, GermanyWiley-VCH2006
   Google Scholar